1 Executive Summary
2 Market Introduction
2.1 Definition 15
2.2 Scope of the Study 15
2.3 Assumptions & Limitations 15
2.3.1 Assumptions 15
2.3.2 Limitations 15
2.4 Market Structure 16
3 Research Methodology
3.1 Research Process 17
3.2 Primary Research 18
3.3 Secondary Research 18
3.4 Market Size Estimation 19
3.5 Top-Down & Bottom-Up Approach 20
3.6 Market forecast 20
4 Market Dynamics
4.1 Introduction 21
4.2 Drivers 22
4.2.1 Rising Prevalence of Major Depressive Disorder (MDD) 22
4.2.2 Growing Importance of Generics 22
4.2.3 Increasing Demand for Atorvastatin Intermediate 22
4.2.4 Rising Incidence of Chronic Diseases 22
4.3 Restraints 23
4.3.1 Rising Healthcare Cost 23
4.3.2 Unfavorable Drug Price Control Policies Across Various Countries 23
4.4 Opportunities 23
4.4.1 Entering Developing Economies 23
4.5 Market Trends 24
4.5.1 Introduction of Innovative Drugs 24
4.6 Macroeconomic Indicators 24
5 Market Factor Analysis
5.1 Value Chain Analysis 25
5.1.1 R&D 25
5.1.2 Manufacturing 25
5.1.3 Distribution & Sales 25
5.1.4 Post-Sales Monitoring 26
5.2 Porter’s Five Forces Analysis 26
5.2.1 Threat of New Entrants 27
5.2.2 Bargaining Power of Suppliers 27
5.2.3 Threat of Substitutes 27
5.2.4 Bargaining Power of Buyers 27
5.2.5 Intense Rivalry 27
5.3 Investment Opportunities 28
5.4 Pricing Analysis 29
5.5 Product Pipeline Analysis 29
5.5.1 Overview 29
5.5.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS 30
5.5.3 Effect of Duloxetine for the Treatment of Chronic Pain due to Osteoarthritis 30
5.5.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain 30
5.5.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder 31
5.5.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy 31
5.5.7 Atorvastatin Calcium Tablets, 40 mg 31
5.5.8 Actual Use Trial of Atorvastatin Calcium 10 mg 32
5.5.9 Atorvastatin Vs. Simvastatin in the Prevention of Coronary Heart Disease (CHD) in Patients with Known CHD 32
5.5.10 Atorvastatin for the Treatment of Pulmonary Sarcoidosis 32
5.5.11 Atorvastatin for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women with Elevated Low-density Lipoprotein (LDL) Cholesterol 33
5.6 Patent Analysis 33
5.6.1 Overview 33
6 Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
6.1 Overview 35
6.2 Duloxetine Intermediates 35
6.3 Atorvastatin Intermediates 36
7 Global Duloxetine Intermediate & Atorvastatin Intermediates Market, By Region
7.1 Overview 43
7.2 Americas 45
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.2.1 North America 47
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.2.1.1 US 48
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.2.1.2 Canada 49
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.2.2 Latin America 50
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3 Europe 52
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.1 Western Europe 54
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.1.1 Germany 56
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.1.2 France 57
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.1.3 UK 58
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.1.4 Spain 59
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.1.5 Italy 60
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.1.6 Rest of Western Europe 61
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.3.2 Eastern Europe 62
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.4 Asia-Pacific 63
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.4.1 China 65
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.4.2 India 66
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.4.3 Japan 67
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.4.4 Rest of Asia-Pacific 68
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.5 Middle East & Africa 69
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.5.1 Middle East 71
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
7.5.2 Africa 72
Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
8 Competitive Landscape
8.1 Introduction 73
9 Company Profiles
9.1 Jiangxi Aifeimu Technology Co., Ltd 85
9.1.1 Company Overview 85
9.1.2 Financial Overview 85
9.1.3 Products/Services Offered 85
9.1.4 Key Developments 85
9.1.5 SWOT Analysis 86
9.1.6 Key Strategies 86
9.2 Zhejiang Jiuzhou Pharmaceutical Co., Ltd 87
9.2.1 Company Overview 87
9.2.2 Financial Overview 87
9.2.3 Products/Services Offered 87
9.2.4 Key Developments 87
9.2.5 SWOT Analysis 88
9.2.6 Key Strategies 88
9.3 Jigs Chemicals 89
9.3.1 Company Overview 89
9.3.2 Financial Overview 89
9.3.3 Products/Services Offered 89
9.3.4 Key Developments 89
9.3.5 SWOT Analysis 90
9.3.6 Key Strategies 90
9.4 Manus Aktteva 91
9.4.1 Company Overview 91
9.4.2 Financial Overview 91
9.4.3 Products/Services Offered 91
9.4.4 Key Developments 91
9.4.5 SWOT Analysis 92
9.4.6 Key Strategies 92
9.5 Arch Pharmalabs 93
9.5.1 Company Overview 93
9.5.2 Financial Overview 93
9.5.3 Products/Services Offered 93
9.5.4 Key Developments 93
9.5.5 SWOT Analysis 94
9.5.6 Key Strategies 94
9.6 Afine Chemicals Ltd 95
9.6.1 Company Overview 95
9.6.2 Financial Overview 95
9.6.3 Products/Services Offered 95
9.6.4 Key Developments 95
9.6.5 SWOT Analysis 96
9.6.6 Key Strategies 96
9.7 Shodhana Laboratories 97
9.7.1 Company Overview 97
9.7.2 Financial Overview 97
9.7.3 Products/Services Offered 97
9.7.4 Key Developments 97
9.7.5 SWOT Analysis 98
9.7.6 Key Strategies 98
9.8 Fluorochem Ltd 99
9.8.1 Company Overview 99
9.8.2 Financial Overview 99
9.8.3 Products/Services Offered 99
9.8.4 Key Developments 99
9.8.5 SWOT Analysis 100
9.8.6 Key Strategies 100
9.9 Chiral Bio Sciences Ltd 101
9.9.1 Company Overview 101
9.9.2 Financial Overview 101
9.9.3 Products/Services Offered 101
9.9.4 Key Developments 101
9.9.5 SWOT Analysis 102
9.9.6 Key Strategies 102
9.10 Tokyo Chemical Industry Co., Ltd 103
9.10.1 Company Overview 103
9.10.2 Financial Overview 103
9.10.3 Products/Services Offered 103
9.10.4 Key Developments 103
9.10.5 SWOT Analysis 104
9.10.6 Key Strategies 104
10 Appendix
10.1 References 100
10.2 Related Reports 100
14 List of Tables
TABLE 1 MARKET SYNOPSIS 15
TABLE 2 PRIMARY INTERVIEWS 19
TABLE 3 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5))AVERAGE SELLING PRICE (ASP), BY REGION, 2020-2027 (USD/KG) 31
TABLE 4 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2020-2027 (USD/KG) 32
TABLE 5 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2020-2027 (USD/KG) 32
TABLE 6 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2020-2027 (USD/KG) 32
TABLE 7 CLINICAL TRIALS 33
TABLE 8 PATENT ANALYSIS FOR GLOBAL DULOXETINE & ATORVASTATIN DRUGS 39
TABLE 9 PROMINENT KEY CUSTOMERS FOR DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES 43
TABLE 10 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 45
TABLE 11 GLOBAL ATORVASTATIN INTERMEDIATES MARKET, BY ATORVASTATIN INTERMEDIATES TYPE, 2020–2027 (USD THOUSAND) 46
TABLE 12 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)) MARKET VOLUME, BY REGION 2020-2027 (TONS) 46
TABLE 13 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)) MARKET VOLUME, BY COUNTRY 2020-2027 (TONS) 47
TABLE 14 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) MARKET VOLUME, BY ERGION 2020-2027 (TONS) 47
TABLE 15 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) MARKET VOLUME, BY COUNTRY 2020-2027 (TONS) 47
TABLE 16 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) MARKET VOLUME, BY REGION 2020-2027 (TONS) 48
TABLE 17 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) MARKET VOLUME, BY COUNTRY 2020-2027 (TONS) 48
TABLE 18 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) MARKET VOLUME, BY REGION 2020-2027 (TONS) 48
TABLE 19 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) MARKET VOLUME, BY COUNTRY 2020-2027 (TONS) 49
TABLE 20 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)), BY REGION, 2020–2027 (USD THOUSAND) 51
TABLE 21 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, BY REGION, 2020-2027 (USD THOUSAND) 51
TABLE 22 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0), BY REGION, 2020-2027 (USD THOUSAND) 52
TABLE 23 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0), BY REGION, 2020-2027 (USD THOUSAND) 52
TABLE 24 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0), BY REGION, 2020-2027 (USD THOUSAND) 53
TABLE 25 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION 2020-2027 (USD THOUSAND) 54
TABLE 26 AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION 2020-2027 (USD THOUSAND) 56
TABLE 27 AMERICAS: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 57
TABLE 28 AMERICAS: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 57
TABLE 29 NORTH AMERICA: AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 58
TABLE 30 NORTH AMERICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 58
TABLE 31 NORTH AMERICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 59
TABLE 32 US: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 59
TABLE 33 US: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 60
TABLE 34 CANADA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 60
TABLE 35 CANADA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 61
TABLE 36 LATIN AMERICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 61
TABLE 37 LATIN AMERICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 62
TABLE 38 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION, 2020–2027 (USD THOUSAND) 63
TABLE 39 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 64
TABLE 40 EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 64
TABLE 41 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 65
TABLE 42 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 66
TABLE 43 WESTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 66
TABLE 44 GERMANY: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 67
TABLE 45 GERMANY: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 67
TABLE 46 FRANCE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 68
TABLE 47 FRANCE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 68
TABLE 48 UK: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 69
TABLE 49 UK: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 69
TABLE 50 SPAIN: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 70
TABLE 51 SPAIN: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 70
TABLE 52 ITALY: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 71
TABLE 53 ITALY: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 71
TABLE 54 REST OF WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 72
TABLE 55 REST OF WESTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 72
TABLE 56 EASTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 73
TABLE 57 EASTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 73
TABLE 58 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 74
TABLE 59 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 75
TABLE 60 ASIA-PACIFIC: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 75
TABLE 61 CHINA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 76
TABLE 62 CHINA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 76
TABLE 63 INDIA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 77
TABLE 64 INDIA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 77
TABLE 65 JAPAN: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 78
TABLE 66 JAPAN: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 78
TABLE 67 REST OF ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 79
TABLE 68 REST OF ASIA-PACIFIC: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 79
TABLE 69 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION, 2020–2027 (USD THOUSAND) 80
TABLE 70 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 81
TABLE 71 MIDDLE EAST & AFRICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 81
TABLE 72 MIDDLE EAST: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 82
TABLE 73 MIDDLE EAST: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 82
TABLE 74 AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2020–2027 (USD THOUSAND) 83
TABLE 75 AFRICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2020-2027 (USD THOUSAND) 83
TABLE 76 TOP MANUFACTURERS IN THE GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET 84
15 List of Figures
FIGURE 1 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET: MARKET STRUCTURE 17
FIGURE 2 RESEARCH PROCESS 18
FIGURE 3 SUPPLY CHAIN: GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET 27
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET 29
FIGURE 5 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY INTERMEDIATE TYPE, 2020(%) 49
FIGURE 6 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY ATORVASTATIN INTERMEDIATES TYPE, 2020(%) 49
FIGURE 7 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY INTERMEDIATE TYPE, 2020 & 2027 (USD THOUSAND) 50
FIGURE 8 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY ATORVASTATIN INTERMEDIATES TYPE, 2020 & 2027 (USD THOUSAND) 50
FIGURE 9 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2020(%) 54
FIGURE 10 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2020 & 2027 (USD THOUSAND) 55
FIGURE 11 AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION 2020 (%) 56
FIGURE 12 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2020 (%) 63
FIGURE 13 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY COUNTRY, 2020 (%) 65
FIGURE 14 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY COUNTRY, 2020 (%) 74
FIGURE 15 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2020 (%) 80
Speak to Analyst
Request a Free Sample
Duloxetine Intermediate and Atorvastatin Intermediates Market Overview
The Duloxetine Intermediate and Atorvastatin Intermediates Market is expected to register a CAGR 4.04% to reach USD 73.5466 million by 2023. Duloxetine intermediate is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is widely approved for the treatment of stress urinary incontinence in women, major depressive disorder (MDD), and other chronic diseases. The atorvastatin intermediate is commonly used in lowering the cholesterol level and helps prevent cardiovascular diseases.
Rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, rising incidence of chronic diseases are expected to enhance the duloxetine intermediate and atorvastatin intermediates market growth. However, factors such as increasing healthcare cost and unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.
Market Dynamics
The duloxetine intermediate and atorvastatin intermediates market has been primarily driven by the rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, and growing incidence of chronic diseases. For instance, as per the survey carried out by the American Heart Association and the American College of Cardiology in 2016, around 37.5% (43.2 million) to 48.6% (56 million) of the US adults were on treatment by atorvastatin intermediate. Factors such as rising healthcare cost, unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.
Global Duloxetine Intermediate and Atorvastatin Intermediates Market Revenue, by Intermediate, 2017 & 2023 (USD Million) 
Sources: MRFR Analysis
Segmentation
The duloxetine intermediate and atorvastatin intermediates market is segmented into an intermediate type. Based on intermediate, the market is bifurcated into duloxetine intermediates and atorvastatin intermediates. Duloxetine Intermediate segment held a duloxetine intermediate and atorvastatin intermediates market share of 32393.03 USD Million in 2017.
Key Players
The prominent players in the Duloxetine Intermediate and Atorvastatin Intermediates market are Jiangxi Aifeimu Technology Co., Ltd, Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Jigs Chemicals, Manus Aktteva, Arch Pharmalabs, Afine Chemicals Ltd, Shodhana Laboratories, Fluorochem Ltd, Chiral Bio Sciences Ltd, Tokyo Chemical Industry Co., Ltd.
Asia-Pacific Duloxetine Intermediate and Atorvastatin Intermediates Market Share, 2017 (%) 
Sources: MRFR Analysis
Regional Analysis
The duloxetine intermediate and atorvastatin intermediates market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounts the largest market share, wherein North America is expected to dominate the market mainly due to the increasing geriatric population and the availability of advanced healthcare facilities in this region.
Europe is anticipated to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are well-established healthcare infrastructure and the increase in adoption of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disease and major mental disorders.
Asia-Pacific is estimated to be the fastest-growing region in the duloxetine intermediate and atorvastatin intermediates market. This can be attributed to developing economies such as China, India, and South Korea emerging as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. Japan held a market share of 18.5% in 2017.
Also, the duloxetine intermediate and atorvastatin intermediates market in the Middle East and Africa region is projected to account for the least share during the review period. The Middle East is expected to influence the market owing to the increasing use of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disorders in Saudi Arabia, Kuwait, and the UAE.
Market Segmentation
Duloxetine Intermediate and Atorvastatin Intermediates Market, by Intermediate Type
- Duloxetine Intermediates
- Atorvastatin Intermediates
Duloxetine Intermediate and Atorvastatin Intermediates Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
Intended Audience
- Duloxetine intermediate & atorvastatin intermediates manufacturers
- Healthcare providers
- Research institutes and academic centers
- Government associations
- Market research and consulting
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size |
|
| CAGR | 4.04% (2018-2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Intermediate type |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Jiangxi Aifeimu Technology Co., Ltd, Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Jigs Chemicals, Manus Aktteva, Arch Pharmalabs, Afine Chemicals Ltd, Shodhana Laboratories, Fluorochem Ltd, Chiral Bio Sciences Ltd, Tokyo Chemical Industry Co., Ltd. |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Duloxetine intermediate and atorvastatin intermediates market is projected to grow at a 4.04% CAGR between 2020-2027.
The Americas is expected to dominate the duloxetine intermediate and atorvastatin intermediates market.
Duloxetine intermediate and atorvastatin intermediates market is predicted to touch USD 73.5466 million by 2023.
The duloxetine intermediates segment will lead the duloxetine intermediate and atorvastatin intermediates market.
Which factors may restrict the duloxetine intermediate and atorvastatin intermediates market growth?
Rising healthcare cost may restrict duloxetine intermediate and atorvastatin intermediates market growth.
